Parkinson's disease (PD ... leading to the degeneration and death of dopaminergic neurons in the substantia nigra of the midbrain. To ameliorate motor symptoms in patients, a common clinical ...

The idea that endogenous progenitor cells might be harnessed to replace neurons lost in neurodegenerative diseases is popular, but requires the development of methods to stimulate their ...

Parkinson’s UK, the largest European charitable ... supporting the function of dopaminergic neurons, and switching on neuron survival signals. And Annovis Bio, a Pennsylvania-based drug platform ...

An enzyme that helps clear damaged mitochondria can act as a molecular switch and potentially prevent neurons from dying.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

There is now robust experimental evidence for a neuroprotective effect of nicotine upon dopaminergic neurons. By contrast, in animal models of Parkinson's disease, nicotine alone has slight or no ...

subjects with early- and late-stage Parkinson's will receive a single dose of the gene therapy, and then be followed up for 18 months to gauge its effects on dopaminergic neurons, as well as ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Parkinson's disease (PD ... leading to the degeneration and death of dopaminergic neurons in the substantia nigra of the midbrain. To ameliorate motor symptoms in patients, a common clinical ...